Podcasts about Medicus

In this episode of The Money Scope Podcast, Benjamin Felix and Dr. Mark Soth (The Loonie Doctor) take a deep dive into the complex world of pensions for incorporated professionals. They unpack the pros and cons of the various pension structures available in Canada—from RRSPs and IPPs to MEPPs—and explain how these compare in terms of tax treatment, investment flexibility, creditor protection, and long-term retirement security. Through their discussion, Ben and Mark illuminate how pensions really work for business owners who are both employer and employee, why "pension envy" can cloud rational decisions, and how evidence and math—not marketing—should guide your retirement planning. They also explore the behavioral and psychological side of pensions: why risk pooling matters, how defined benefit plans manage longevity and sequence risk, and when the added complexity of an IPP or MEPP might actually be worth it. This is one of the most comprehensive overviews of pensions you'll hear—combining research, real-world application, and practical insight for anyone trying to optimize their corporate retirement strategy.   Key Points From This Episode: Why pensions matter for Canadian business owners—and why this episode took a while to make. (0:01:20) Canada's three-pillar retirement system: public pensions, employer-sponsored pensions, and personal savings. (0:02:16) The pension landscape: RRSPs, individual pension plans (IPPs), and multi-employer pension plans (MEPPs). (0:03:19) Defined contribution (DC) vs. defined benefit (DB) pensions—who bears the investment risk. (0:06:24) How MEPPs like Medicus and HOOPP allow incorporated professionals to join group plans. (0:08:54) The truth behind branded pension products—why the legislative structure is what really matters. (0:10:20) Pension envy and the economics of compensation: who actually pays for "employer contributions." (0:12:27) Comparing RRSPs and pensions: tax deferral, limits, and liquidity differences. (0:14:55) RRSP flexibility vs. pension restrictions in withdrawals and contributions. (0:17:54) Defined benefit vs. defined contribution pensions—how risk and control shift between employer and employee. (0:22:57) Why small business owners often prefer IPPs after age 40. (0:25:20) What happens to pensions in retirement: RRSPs → RRIFs, pensions → LIRAs/LIFs. (0:29:06) Group pensions vs. individual pensions: pooling risks and costs. (0:31:34) Do big pensions really have investment advantages? A data-driven look at costs and active management. (0:33:18) Why institutional investors often underperform passive portfolios—even with elite managers. (0:39:24) CPP Investments as a case study: $700B in assets, billions in fees, and lagging benchmarks. (0:42:24) Evaluating pensions on liabilities, not just returns—what "immunizing liabilities" means. (0:45:45) Sequence-of-returns and longevity risk: why pooling helps retirees sleep better. (0:48:46) Behavioral finance and the comfort of cash buffers in retirement planning. (0:53:48) The trade-offs of pooling mortality risk—winners, losers, and stability. (0:57:56) Individual Pension Plans (IPPs): what they are, how they're structured, and when they make sense. (1:02:10) Contribution limits and past-service buybacks—why IPPs become powerful after age 40. (1:05:40) How spouses can be included in an IPP—and the nuances of spousal RRSPs. (1:09:39) The importance of actuarial valuations and how contribution "holidays" or "top-ups" work. (1:11:27) IPPs in practice: shifting corporate pre-tax dollars into a tax-sheltered pension efficiently. (1:14:38)   Links From Today's Episode: Medicus Pension Plan — https://www.medicuspensionplan.com/  HOOPP (Healthcare of Ontario Pension Plan) — https://hoopp.com/  Canada Pension Plan Investments — https://www.cppinvestments.com/  PWL Capital — https://pwlcapital.com/  Dr. Mark Soth (The Loonie Doctor) — https://www.looniedoctor.ca/ Dr. Mark on X — https://x.com/LoonieDoctor Benjamin Felix — https://www.pwlcapital.com/author/benjamin-felix/  Benjamin on X — https://x.com/benjaminwfelix Benjamin on LinkedIn — https://www.linkedin.com/in/benjaminwfelix/ Money Scope on YouTube — https://www.youtube.com/@MoneyScopePodcast

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that the company has received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical trial evaluating its Doxorubicin Microneedle Array technology for the non-invasive treatment of basal cell carcinoma of the skin. The study, known as SKNJCT-003, is already underway across nine clinical sites in the United States and will now broaden to include additional sites in the U.K., following this latest approval milestone. Dr. Bokhari explained that approvals were issued by the Medicines and Healthcare products Regulatory Agency , the Health Research Authority (HRA), and the Wales Research Ethics Committee. The MHRA's authorization came after a comprehensive scientific review of the Investigational Medicinal Product Dossier and clinical protocol, while WREC issued a favorable ethical opinion. The HRA subsequently granted study-wide governance approval, confirming full compliance with U.K. Good Clinical Practice (GCP) and National Health Service (NHS) capacity and capability standards. The Phase 2 trial is designed as a randomized, double-blind, placebo-controlled, multi-center study enrolling up to 90 patients with BCC. It aims to evaluate the efficacy and safety of two dose levels of D-MNA compared to a placebo control. Participants will be randomized into three groups in a 1:1:1 ratio, a placebo-controlled group, a low-dose group, and a high-dose group. Dr. Bokhari highlighted that the 200 μg high-dose level represents the maximum dose previously tested in Medicus Pharma's Phase 1 safety and tolerability study, which was successfully completed in March 2021. The company views the U.K. expansion as a significant step toward advancing its novel microneedle drug delivery platform and potentially transforming the treatment landscape for non-melanoma skin cancers through a minimally invasive, localized therapy that may reduce the need for surgery and improve patient outcomes. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #GorlinSyndrome #BasalCellCarcinoma #CompassionateUse #FDAApproval #RareDiseaseTreatment #NoninvasiveTherapy #BiotechNews

LA BIBLIOTECA DE LA HISTORIA nos abre uno de sus archivos, que nos va a acercar a: "Medicus. La medicina en la Antigua Roma (La Sociedad Romana VII)" Hoy tenemos un nuevo programa con el escritor y divulgador histórico Ángel Portillo Lucas en el que nos va hablar de su nueva novela histórica titulada "Medicus", en la que nos sumerge en otra fascinante aventura ambientada en la Antigua Roma y en la que tenemos como base fundamental cómo era vista y usada la medicina en aquella sociedad de las que nos separan casi dos mil años de historia. Sin más preámbulos os dejo con el programa y espero que os guste. Enlace al libro "Medicus": https://amzn.to/3Jzpa8A Enlace al libro "Rómulo y las Sabinas": https://amzn.to/3WDpLZR Enlace al libro "Hércules. El Dios de Trajano": https://amzn.to/3Jv7s69 Enlace al libro "Lignvm": https://amzn.to/3WDRJ7R Enlace al libro "Lignvm en Roma": https://amzn.to/3JPbPJj Enlace al libro "Lignvm en Tapae": https://amzn.to/49nPcpZ Enlace al libro "Cunina. Diosa tutelar de la infancia": https://amzn.to/4orhrsc Enlace al libro "Aliso. Los últimos supervivientes de Teutoburgo": https://amzn.to/4qMeC6O Enlace al libro "Juno y las matronas romanas": https://amzn.to/3LoJ8Dw Ángel Portillo Lucas es profesor y escritor. Tiene un blog dedicado a la divulgación de la historia de Roma, concretamente a esos aspectos menos conocidos por el público en general. Hasta el momento ha publicado ocho novelas históricas sobre la Antigua Roma, tres de ellas que pertenecen a la trilogía "LIGNVM", como son "LIGNVM" , "LIGNVM EN TAPAE" y "LIGNVM EN ROMA", otras tres novelas que pertenecen a la serie "Crónicas Romanas" como son "Cunina, Diosa tutelar de la infancia", "Aliso, los últimos supervivientes de Teutoburgo" y "Juno y las matronas romanas"; y también tiene otras dos novelas como son "Hércules, el Dios de Trajano" y "Rómulo y las Sabinas". También tiene un podcast dedicado a la divulgación histórica y es miembro de la asociación "Divulgadores de la Historia". -Blog de Ángel Portillo: http://lignumenroma.blogspot.com/ -Podcast Lignvm en Roma: https://www.ivoox.com/podcast-lignum-roma_sq_f1828941_1.html -Canal de YouTube de Ángel Portillo Lucas: https://www.youtube.com/channel/UCksX17gHXmmhRVchvrIopuQ -Canal de YouTube Sergio Alejo - Calamares a la romana: https://www.youtube.com/c/SergioAlejoGomezEscritor Este es un Podcast producido y dirigido por Gerión de Contestania, miembro del grupo "Divulgadores de la Historia". -Enlace a la página web de Divulgadores de la Historia: https://divulgadoresdelahistoria.wordpress.com/ Somos un podcast perteneciente al sello iVoox Originals. -Canal de YouTube de LA BIBLIOTECA DE LA HISTORIA: https://www.youtube.com/channel/UCfHTOD0Z_yC-McS71OhfHIA Correo electrónico: labibliotecadelahistoria@gmail.com *Si te ha gustado el programa dale al "Like", ya que con esto ayudarás a darnos más visibilidad. También puedes dejar tu comentario, decirnos en que hemos fallado o errado y también puedes sugerir un tema para que sea tratado en un futuro programa de LA BIBLIOTECA DE LA HISTORIA. Gracias. Música del audio: -Entrada: Epic Victory by Akashic Records . License by Jamendo. -Voz entrada: http://www.locutordigital.es/ -Relato: Music with License by Jamendo. Redes Sociales: -Twitter: LABIBLIOTECADE3 -Facebook: Gerión De Contestania Muchísimas gracias por escuchar LA BIBLIOTECA DE LA HISTORIA y hasta la semana que viene. Podcast amigos: Niebla de Guerra: https://www.ivoox.com/podcast-niebla-guerra_sq_f1608912_1.html La Biblioteca Perdida: https://www.ivoox.com/podcast-podcast-la-biblioteca-perdida_sq_f171036_1.html Casus Belli: https://www.ivoox.com/podcast-casus-belli-podcast_sq_f1391278_1.html Victoria Podcast: https://www.ivoox.com/podcast-victoria-podcast_sq_f1781831_1.html Relatos Salvajes: https://www.ivoox.com/podcast-relatos-salvajes_sq_f1470115_1.html Motor y al Aire: https://www.ivoox.com/podcast-motor-al-aire_sq_f1117313_1.html Pasaporte Historia: https://www.ivoox.com/podcast-pasaporte-historia_sq_f1835476_1.html Cita con Rama Podcast: https://www.ivoox.com/cita-rama-podcast-ciencia-ficcion_sq_f11043138_1.html Sierra Delta: https://www.ivoox.com/podcast-sierra-delta_sq_f1507669_1.html Permiso para Clave: https://www.ivoox.com/podcast-permiso-para-clave_sq_f1909797_1.html Héroes de Guerra 2.0: https://www.ivoox.com/podcast-heroes-guerra_sq_f1256035_1.html Calamares a la Romana: https://www.ivoox.com/podcast-calamares-a-romana_sq_f12234654_1.html Lignvm en Roma: https://www.ivoox.com/podcast-lignum-roma_sq_f1828941_1.html Bestias Humanas: https://www.ivoox.com/podcast-bestias-humanas_sq_f12390050_1.html Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to unveil a new strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, the company's investigational doxorubicin-containing dissolvable microneedle array therapy for basal cell carcinoma. The initiative focuses on patients with Gorlin Syndrome—also known as nevoid basal cell carcinoma syndrome—a rare genetic condition that affects an estimated 1 in 31,000 people worldwide. Individuals diagnosed with the disorder can develop hundreds or even thousands of BCCs throughout their lives, often beginning in childhood. Current treatment approaches frequently involve repeated surgeries and ongoing dermatologic interventions, resulting in significant physical scarring, emotional strain, and financial burden. Dr. Bokhari explained that the partnership with the GSA is designed to jointly pursue an Expanded Access IND Program with the U.S. Food and Drug Administration (FDA). This pathway would enable eligible Gorlin Syndrome patients with multiple, recurrent, or inoperable basal cell carcinomas to obtain supervised treatment with SKINJECT™ outside of traditional clinical trials. In addition to facilitating treatment for those with pressing unmet medical needs, the program will support the collection of real-world safety and tolerability data, which will contribute to future regulatory submissions. It will also enable greater incorporation of patient-centered insights into clinical development and long-term treatment strategies. Medicus Pharma is currently underway with its Phase 2 clinical study, SKNJCT-003, which began enrolling patients in August 2024 across nine U.S. trial sites. The study is a double-blind, placebo-controlled, triple-arm proof-of-concept trial evaluating SKINJECT™ as a non-invasive therapeutic option for skin-based BCC using proprietary dissolvable D-MNA . Dr. Bokhari emphasized that the collaboration with the GSA reflects Medicus Pharma's mission to bring innovative, patient-friendly cancer treatments to those most in need, while advancing SKINJECT™ toward broader clinical and commercial milestones. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #GorlinSyndrome #BasalCellCarcinoma #CompassionateUse #FDAApproval #RareDiseaseTreatment #NoninvasiveTherapy #BiotechNews

⚠️ Uwaga:Nie opowiadam w nim całej historii głównego bohatera, ani nie zdradzam zakończenia. – bo tego masz doświadczyć sam, po własnej lekturze. Ale obiecuję: to, co usłyszysz, zmieni Twój sposób myślenia o determinacji.Jeśli jednak nie chcesz nic wiedzieć o jej głównym bohaterze, nie słuchaj tego odcinka.

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce a major clinical milestone — the enrollment of the first patient in the company's SKNJCT-004 Phase 2 clinical trial in the United Arab Emirates (UAE). The study aims to evaluate a non-invasive treatment for basal cell carcinoma (BCC), the most common form of skin cancer. The multi-center, double-blind, placebo-controlled trial will enroll 36 patients across six leading medical institutions in the UAE, including Cleveland Clinic Abu Dhabi, Sheikh Shakbout Medical City, Burjeel Medical City, Rashid Hospital, Clemenceau Medical Center, and American Hospital of Dubai. Dr. Bokhari explained that the study will assess the efficacy and safety of two dose levels of Medicus Pharma's proprietary D-MNA (drug-coated microneedle array) compared to a placebo control. Participants will be randomized into three groups, a placebo-controlled group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA. The 200μg dose represents the maximum level previously used in the company's successful Phase 1 safety and tolerability trial (SKNJCT-001), completed in March 2021. Dr. Bokhari emphasized that this next phase marks a significant step forward for Medicus Pharma's mission to develop non-invasive dermatological treatments that can potentially eliminate the need for surgical excision in certain skin cancer cases. With recruitment underway and multiple top-tier hospitals participating, the SKNJCT-004 study positions Medicus Pharma at the forefront of innovative, patient-friendly oncology solutions in the Middle East and beyond. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation

¡Vótame en los Premios iVoox 2025! Retomamos el tema con el que arrancamos la presente temporada hace unas semanas: la unificación de Japón. Con la sabia guía de Rubén Ibarzabal, ya os explicamos la era Sengoku, caracterizada por el caos bélico con señores de la guerra luchando por doquier. Hoy conoceremos a los tres grandes nombres que lograron poner fin a ese periodo, con el anhelo de establecer un mando unificado en el país del sol naciente. Hablamos de Oda Nobunaga, Toyotomi Hideyoshi y Tokugawa Ieyasu. La segunda propuesta nos lleva a conocer el oficio de galeno en la antigua Roma. Y nunca mejor dicho, porque el hombre que llegó su nombre al vocabulario como sinónimo de médico, tiene su papel en la última novela de Ángel Portillo, Medicus, publicada el pasado verano. Lo entrevistamos para conocer todos sus entresijos. En la repetición, esta semana recuperamos la tercera parte de la saga sobre los cosacos. Tras repasar su forma de vida retomamos el repaso a la historia de este pueblo. Partiendo del siglo XVII nos detendremos en las rebeliones protagonizadas por cosacos, recordaremos su notable participación en la campaña rusa de Napoleón y veremos su rol en la conquista del Cáucaso y de Asia Central. Cerramos la entrega a las puertas de la Revolución Rusa de 1917. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that the company has received encouraging feedback from its recent Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the clinical development pathway of its innovative microneedle-based therapy, Skinject™ (D-MNA), for the treatment of basal cell carcinoma (BCC). The Type C meeting focused on reviewing key elements of the protocol, including study design, endpoints, and patient population definitions for upcoming clinical trials. According to Dr. Bokhari, the FDA provided clarity and alignment on several critical points. Specifically, the agency indicated that a relative bioavailability study with D-MNA, administered under certain conditions, could serve as a basis for establishing a regulatory bridge while addressing bioavailability requirements for the product. Importantly, the FDA offered constructive and supportive guidance on multiple aspects of the proposed development program, including the appropriate primary endpoint for the next clinical study. The company must define the patient population, such as tumor size limits, lesion location restrictions, and histological confirmation requirements and design a randomized, double-blind, placebo-controlled trial to demonstrate efficacy in treating BCC. This regulatory clarity is expected to further strengthen Medicus Pharma's ongoing clinical program. The company is currently conducting its Phase 2 trial across nine clinical sites in the United States. Patient randomization began in August 2024. In March 2025, Medicus Pharma announced results from an interim analysis of the Phase 2 study, showing a positively trending clinical clearance rate exceeding 60%. The interim data, based on more than half of the targeted 60 patients randomized at the time, were highly encouraging, although final results may vary once the study is fully completed. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation

Philipp Medicus setzt bei der Entwicklung von Gleitschirmen für Nova stark auf die Hilfe von Simulationsprogrammen. Was bringt das? +++ Es gab eine Zeit, da war die Konstruktion von Gleitschirmen vor allem ein Handwerk. Da wurden Profile noch aus Pappe geschnitten, um dann darauf die Tuchbahnen abzuwickeln und so letztendlich zu den Schnittmustern zu kommen. Und wenn es gut lief, sank so ein Schirm am Ende nicht nur mit Gleitzahl eins zu Stein vom Himmel. Im modernen Gleitschirmbau ist der Computer zum vielleicht wichtigsten Werkzeug der Konstrukteure geworden. Immer mehr spielen dabei nicht nur CAD-Software, sondern auch komplexere Simulationen der Strömungsdynamik eine Rolle. Philipp Medicus von Nova geht sogar noch einen Schritt weiter. Er nutzt Programme, die die dynamische Verformung eines Gleitschirms berechnen können, wenn aerodynamischen Kräfte ins Wechselspiel treten mit Dutzenden anderer technischer Parameter, die einen Gleitschirm ausmachen: Profilform, Zellenzahl, Leinenlayout, Querzugbänder, Diagonalrippen, 3D-Shaping, Mini-Ribs, etc. In dieser Episode 170 von Podz-Glidz erzählt Philipp Medicus, wie diese Herangehensweise ihm dabei hilft, Gleitschirme zu bauen, die auch in bewegter, turbulenter Luft noch möglichst stabil und leistungsstark bleiben. Im Gespräch geht es auch um Fragen wie: Wann ist das Konzept Gleitschirm auskonstruiert? Wie entsteht eigentlich ein Pflichtenheft für ein neues Modell? Und welche Rolle spielt heute schon KI in der Entwicklung von Gleitschirmen? +++ Werde zum Förderer von Podz-Glidz und dem Blog Lu-Glidz. Alle Infos: https://lu-glidz.blogspot.com/p/fordern.html +++ Musik dieser Folge: Track: Spatial Entaglement | Künstler: The Grey Room Youtube Audio Library https://www.youtube.com/watch?v=s5VdA6spQeY +++ Lu-Glidz Links: + Blog: https://lu-glidz.blogspot.com + Facebook: https://www.facebook.com/luglidz + Instagram: https://www.instagram.com/luglidz/ + Whatsapp-Kanal: https://whatsapp.com/channel/0029VaBVs05CHDynzdlJlU34 + Youtube: https://youtube.com/@Lu-Glidz + Soundcloud: https://soundcloud.com/lu-glidz + Spotify: https://open.spotify.com/show/6ZNvk83xxGHHtfgFjiAHyJ + Apple-Podcast: https://itunes.apple.com/de/podcast/podz-glidz-der-lu-glidz-podcast/id1447518310?mt=2 + Linktree: https://linktr.ee/luglidz +++ LINKS zu Philipp Medicus + Nova: https://www.nova.eu + Vortrag Thermikmesse zu neuen Möglichkeiten in der Gleitschirmentwicklung: https://www.youtube.com/watch?v=mUZD5Tij1SA

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce a major milestone for the company's dermatology pipeline: the commencement of patient recruitment for its SKNJCT-004 Phase 2 clinical study, designed to non-invasively treat basal cell carcinoma of the skin. The trial has officially begun enrolling participants at the Cleveland Clinic Abu Dhabi, following earlier “study may proceed” approval granted by the UAE Department of Health. Bokhari explained that the study is expected to randomize 36 patients across four leading medical centers in the UAE. In addition to Cleveland Clinic Abu Dhabi, recruitment is set to begin at several other prominent institutions, including Sheikh Shakbout Medical City, Burjeel Medical City, Rashid Hospital, Clemenceau Medical Center, and the American Hospital of Dubai. This multi-center approach aims to accelerate enrollment while ensuring the study draws on a broad and diverse patient population. The SKNJCT-004 trial will assess the efficacy of two dose levels of Medicus Pharma's investigational therapy D-MNA compared to a placebo control. Participants will be randomized in a 1:1:1 ratio into three groups: a placebo group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA. The company believes that a non-invasive therapy could transform the standard of care for BCC by offering patients an alternative to surgery or other destructive modalities. Bokhari also highlighted that Medicus Pharma continues to advance its broader clinical program targeting BCC. The company's SKNJCT-003 Phase 2 study is currently underway at nine clinical sites across the United States, with patient randomization having commenced in August 2024. In March 2025, the company reported a positively trending interim analysis from SKNJCT-003, demonstrating more than 60% clinical clearance—an encouraging early indicator of the therapy's potential efficacy. The company has also closed its acquisition of Antev, a UK-based biotech focused on next-generation gonadotrophin releasing hormone antagonists, noting the company now controls three FDA-approved clinical studies. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to share a series of important corporate and clinical updates, including regulatory progress with the U.S. Food and Drug Administration (FDA), advancement of its Phase 2 study, and a strengthened financial position. Bokhari explained that the FDA has accepted the Company's Type C meeting request, which provides an opportunity for Medicus to engage directly with the agency on the development pathway for its novel D-MNA (SKNJCT-003) technology. The company has formally submitted its queries in writing and expects to receive a response from the FDA before the end of Q3 2025. The purpose of the Type C meeting is to gain further alignment with the FDA on the clinical development strategy, including the potential to fast-track the program. Bokhari emphasized that this interaction is critical for advancing Medicus Pharma's vision of bringing its non-invasive therapy for basal cell carcinoma (BCC) closer to patients. Meanwhile, the Company's Phase 2 clinical trial evaluating the novel D-MNA approach for treating BCC continues to make strong progress. More than 75% of the planned 90 patients have now been randomized into the study, keeping the program on track to achieve enrollment targets. In addition to regulatory and clinical milestones, Medicus reported Q2 2025 financial results that highlight a substantially improved balance sheet. The Company added $11.5 million in aggregate net proceeds from financing transactions and warrant exercises during the quarter. As a result, cash and cash equivalents grew to $9.7 million at the end of Q2, up significantly from $4.0 million at the end of Q1 2025. This financial strength supports the continued advancement of its clinical pipeline, pursuit of strategic transactions, and the ongoing buildout of its core management team. Bokhari noted that the combination of regulatory momentum, clinical trial progress, and financial flexibility positions Medicus Pharma to accelerate the development of its innovative D-MNA platform and advance toward potential future commercialization opportunities. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce the signing of a non-binding Memorandum of Understanding (MoU) with biotechnology firm HelixNano, aimed at co-developing thermostable mRNA-based vaccines by combining their respective proprietary technologies. The collaboration intends to merge HelixNano's advanced mRNA vaccine platform with Medicus' dissolvable microneedle array (MNA) delivery system, with the goal of creating needle-free, thermostable vaccines that can overcome cold-chain logistics, reduce distribution costs, and significantly enhance global accessibility. Dr. Bokhari noted that both companies are in active negotiations to form a joint venture that will lead the co-development and commercialization of these next-generation vaccines. As part of the preliminary work, Medicus and HelixNano have agreed to begin research and production of clinical-grade mRNA vaccine-loaded MNAs for use in a Phase 1 clinical bridging study. This study will compare the safety and early efficacy of traditional intramuscular injection versus intradermal microneedle delivery using HelixNano's HN-0001 vaccine candidate. Bokhari stated, “Combining HelixNano's potent mRNA vaccine science with our dissolvable microneedle array technology has the potential to redefine how vaccines are delivered worldwide—without needles, without refrigeration, and at scale. This could place us at the forefront of a paradigm shift in infectious disease prevention.” The MoU formalizes the mutual intent to collaborate while both parties work to finalize the terms of the proposed joint venture. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation

In dieser Folge: Silke spricht mit Prof. Dr. Dietrich Grönemeyer über Heilung in schweren Zeiten, über Selbstverantwortung, Angst, Vertrauen und eine Medizin, die Herz und Verstand verbindet. Ein Gespräch über Mut, Eigenverantwortung und die Kraft, die in jedem Menschen selbst liegt. Prof. Grönemeyer zeigt, dass Heilung kein Rezept ist, sondern ein individueller Weg, den wir selbst mitgestalten dürfen. Ein Gespräch, das wachrüttelt, berührt und neue Perspektiven schenkt. Du erfährst: ✨ Wie Du Angst als Chance zur Veränderung sehen kannst ✨ Wie Vertrauen nach Krankheit oder Trauma wieder wachsen kann ✨ Warum Zuhören das wichtigste Instrument in der Medizin ist ✨ Warum echte Heilung immer bei Dir selbst beginnt Lieblingssatz: „Die Heilerin steckt in Dir selbst.“ Diese Folge ist für Dich, wenn… … Du Deinen eigenen Heilungsweg finden und selbstbestimmt gestalten möchtest … Du spüren willst: Du bist nicht allein und es gibt immer Möglichkeiten … Du erfahren möchtest, warum Du mehr Einfluss auf Heilung hast, als Du glaubst Mehr über Prof. Dr. Dietrich Grönemeyer:

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce key developments following the company's annual and special meeting of shareholders, held in July. Bokhari reported that shareholders voted overwhelmingly in favor of all resolutions, including the election of all eight director nominees—two of whom are new to the board. Among the newly elected directors is The Honorable Cathy McMorris Rodgers, a veteran public servant with more than three decades of leadership experience. McMorris Rodgers represented Washington's 5th Congressional District from 2004 to 2025 and previously served as Republican Leader in the Washington State House of Representatives—the first woman to hold that role. Bokhari described her as a people-first, mission-driven leader whose policy acumen and bipartisan leadership will bring tremendous value to Medicus Pharma during its next phase of growth. Also joining the board is Ajay Raju, a well-known attorney, venture capitalist, and entrepreneur. Raju is Chairman and CEO of Raju LLP, Managing Partner of 215 Capital, and Co-founder of Avstera Therapeutics, with leadership roles across 16 portfolio companies. His legal, financial, and strategic expertise further strengthens the company's board as it advances clinical development and business expansion. In addition to governance updates, Bokhari revealed that Medicus has submitted a comprehensive briefing package to the U.S. Food and Drug Administration (FDA) requesting a Type C meeting. The company is seeking formal FDA feedback on its D-MNA (Dermal Methylnaltrexone) development program aimed at treating Basal Cell Carcinoma (BCC) of the skin. The proposed Phase 2 clinical trial (SKNJCT-003) will be a randomized, double-blind, placebo-controlled, multi-center study enrolling up to 60 participants. Subjects will be randomly assigned in equal numbers to receive either a Placebo, low-dose D-MNA, or high-dose D-MNA. The trial is designed to evaluate efficacy and safety outcomes, with the goal of accelerating the development of a novel topical therapy for one of the most common forms of skin cancer. With a strengthened leadership team and a clear regulatory strategy, Medicus Pharma is positioning itself for a pivotal year ahead in both corporate development and clinical advancement. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce a transformational acquisition, with the company entering into a definitive agreement to acquire Antev, a U.S.-based clinical-stage biopharmaceutical firm. The acquisition positions Medicus Pharma to significantly expand its pipeline into high-impact therapeutic areas, particularly in urology and men's health. Under the terms of the agreement, Antev shareholders may receive up to US$65 million in additional contingent consideration, depending on the successful achievement of future milestones, including FDA Phase 2 and New Drug Application (NDA) approvals, as outlined in the definitive agreement. Antev is currently developing Teverelix, a next-generation GnRH antagonist being advanced as a first-in-market therapeutic for two high-need indications: cardiovascular high-risk prostate cancer patients and men experiencing their first episode of acute urinary retention (AURr) due to benign prostatic hyperplasia (BPH), commonly referred to as enlarged prostate. In addition to its pipeline expansion, Medicus Pharma is reinforcing its executive leadership to support its rapidly scaling global operations. Dr. Bokhari announced the appointment of Andrew Smith as Chief Operating Officer, bringing experience from Aberdeen Asset Management to help guide the company's growth across North America, the Middle East, and Southeast Asia. To further strengthen governance and regulatory engagement, the company has nominated former U.S. Congresswoman Cathy McMorris Rodgers—who previously chaired the House Energy and Commerce Committee—to join its board. Her expertise in healthcare policy and FDA relations is expected to be instrumental as Medicus navigates the next phase of clinical and regulatory milestones. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce the submission of a comprehensive product development plan to the U.S. FDA for the treatment of external squamous cell carcinoma (SCC) in horses. The submission was made under the Investigational New Animal Drug (INAD) program and seeks concurrence under the Minor Use in Major Species (MUMS) designation. The FDA recently granted MUMS designation to Medicus Pharma's dissolvable Doxorubicin-containing microneedle array, which is specifically designed to treat external SCC in equine patients. This recognition enables the company to pursue regulatory pathways designed to support treatments for rare conditions in major animal species. Dr. Bokhari explained that SCC is a skin tumor commonly affecting adult or aging horses with white or partially white coats. Breeds such as Appaloosa, Belgian, American Paint, and Pinto are particularly vulnerable. The incidence of SCC in horses is estimated at 2-3%, with the U.S. horse population currently ranging from 6.6 to 7.25 million animals. Current treatment options involve surgical removal of larger tumors, cryotherapy for smaller lesions, and localized or topical chemotherapy. Some cases are also managed with oral medications like piroxicam to slow cancer recurrence. Bokhari noted that the company's microneedle platform could offer a less invasive and more targeted treatment alternative. With the development plan now submitted, Medicus Pharma is aiming to align with the FDA on next steps to bring this innovative treatment to market, providing a new option for veterinarians and horse owners dealing with equine SCC. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation VeterinaryOncology #HorseCancer #SquamousCellCarcinoma #FDAApproval #AnimalHealth

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive that the company has received regulatory approval from the UAE Department of Health to proceed with its Phase 2 clinical trial (SKNJCT-004) for the non-invasive treatment of basal cell carcinoma (BCC) of the skin. The study will enroll 36 patients across four sites in the UAE: Cleveland Clinic Abu Dhabi, Sheikh Shakhbout Medical City, Burjeel Medical City, and American Hospital of Dubai. SKNJCT-004 is a randomized, double-blind, placebo-controlled, multi-center study designed to evaluate the efficacy of two dose levels of D-MNA (Dermal Micro-Needle Array) compared to placebo. Participants will be randomly assigned in a 1:1:1 ratio to receive either a placebo (P-MNA), 100μg of D-MNA (low dose), or 200μg of D-MNA (high dose) The 200μg dose was previously tested as the maximum dose in Medicus Pharma's Phase 1 safety and tolerability study (SKNJCT-001), completed in March 2021. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce a major strategic move: the company has entered into a binding letter of agreement to acquire Antev Ltd., a clinical-stage biotech company. Antev is developing Teverelix, a next-generation GnRH antagonist aimed at treating cardiovascular high-risk prostate cancer patients and patients with acute urinary retention (AUR) due to enlarged prostate. Bokhari highlighted that the acquisition will significantly strengthen Medicus Pharma's drug development portfolio, positioning Teverelix as a first-in-class therapeutic to prevent AUR recurrence and address prostate cancer among patients with elevated cardiovascular risk—together representing a combined market opportunity of approximately $6 billion. Antev's program includes an FDA-approved Phase 2b study, which is designed to randomize 390 men after successfully weaning off catheterization. This is highly relevant given that 85% of the nearly one million AUR episodes annually in the U.S. occur in men over the age of 60. Roughly 30% of these patients experience a recurrent episode within six months, creating a standalone $2 billion annual market for preventive treatment. Teverelix, therefore, offers a critical and differentiated solution in a space underserved by existing therapies, with the potential to redefine standards of care for aging male populations. The acquisition also aligns with Medicus Pharma's mission to build a diversified pipeline targeting significant unmet medical needs with strong commercial potential. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch

Wer ist Yves Nordmann? Dr. Yves Nordmann ist nicht nur praktizierender Kinderarzt mit eigener Praxis in Zürich, sondern auch einer der visionärsten digitalen Gesundheitsunternehmer Europas. Mit einem schweizerisch-israelischen Hintergrund und einer tiefen Verwurzelung in Medizin und Technik hat er Unternehmen wie Welldoc, Oviva, e-Medicus, docdok.health und docjo.health mitgegründet. Seine Mission: medizinisches Fachpersonal entlasten, Patient:innen empowern […] Der Beitrag Dr. Yves Nordmann über Vision, Daten und Vertrauen: Wie ein digital denkender Arzt unser Gesundheitssystem verändern will erschien zuerst auf Visionäre der Gesundheit.

Michael Kirsty of the Friends of Chamber Music Troy is in conversation about upcoming Medicus Memorial Concert Hudson Mohawk Magazines' Andrea Cunliffe asked about the scheduling of artists in these turbulent times when all the Arts need sustaining.. For more information: Friends of Chamber Music.org Medicus Memorial Concert takes place on Wed, Mar 26 @ 7:00 PM at Main Stage, Performing Arts Center, University at Albany SUNY

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce significant progress in the company's Phase 2 clinical study, currently being conducted across nine clinical sites in the United States. The study has now randomized over 50% of its expected 60 patients. The company remains on track to complete an interim data analysis by Q1 2025 and plans to submit its findings to the U.S. Food and Drug Administration (FDA) as part of a Type C meeting request in Q2 2025. The purpose of this meeting is to discuss the clinical development pathway and potentially secure FDA approval to fast-track the program. The SKNJCT-003 clinical trial is a randomized, double-blind, placebo-controlled, multi-center study designed to assess the efficacy of two dose levels of D-MNA in treating basal cell carcinoma (BCC) of the skin. Patients are being randomized into three groups. The 200μg high-dose of D-MNA was previously tested in Medicus Pharma's Phase 1 safety and tolerability study (SKNJCT-001), completed in March 2021. With enrollment progressing and regulatory discussions on the horizon, Medicus Pharma is positioned to accelerate its clinical program, potentially bringing an innovative treatment for BCC closer to market approval. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch

I denne episoden snakker vår fertilitetscoach Mari Fevaag Heger med fertilitetsspesialist Gurpreet Singh Kalra. Gurpreet har lang erfaring innen fertilitet og assistert befruktning. Han har blant annet studert og jobbet i India, Danmark, England, Wales og Norge. Det er ingen tvil om at han elsker jobben som som fertilitetslege og er glad for å kunne hjelpe sine pasienter. Gurpreet er spesialt innen kvinnehelse og fertilitet. Han har over 25 år med erfaring innen assistert befruktning og fertilitetskirurgi. Han har også en spesiell interesse for forskning og for han er det viktig å være oppdatert innen fagfeltet, og samtidig ivareta den psykososiale helsen til pasientene. Vi er så heldig at Gurpreet begynner som IVF lege hos oss på Medicus i Oslo. Episoden vil både gjøre deg litt bedre kjent med Gurpreet og samtidg høre hans tanker om hva som skal til for å lykkes med behandling. Vi ønsker Gurpreet varmt velkommen til oss i Medicus og god lytting til deg!

Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma, has developed a novel, non-invasive treatment for basal cell carcinoma, the most common form of skin cancer. This cost-effective transdermal Skinject patch delivers a chemotherapeutic agent applied in a clinician's office over three sessions to remove the lesion, potentially avoiding the need for Mohs surgery, the current standard of care. Medicus is incorporating AI and advanced imaging techniques in its clinical trials to improve diagnosis and monitoring of the treatment's effectiveness.   Raza explains, "The gold standard to treat basal cell carcinoma of the skin is surgical intervention, generally speaking, all solid tumors to eliminate cancer if it is caught in the early stage. The treatment regimen is that you surgically take the malignant cells out. The same is true for basal cell carcinoma of the skin. It is a slow-growing cancer. It appears on areas of the body that are exposed to ultraviolet radiation, which is being exposed primarily to the sun. When the lesion appears and is diagnosed, the treatment available is what is called Mohs surgical procedure, which is a micrographic go around the lesion of the cancer and just curate out the cancer cells in a surgical suite done by an experienced surgeon."   "We are trying to disrupt by delivering a known chemotherapeutic agent through these uniquely designed, cellulose-based microneedle arrays, which can penetrate the dermis and deliver a chemotherapeutic agent at the site of the lesion and kill the cancer cells, thereby eliminating the need of surgical intervention." "It is currently in clinical trial, but post-approval, it is ready to commercialize. We hope that the dermatologists who are also trained to do Mohs surgery before scheduling the surgery, which usually takes about six to eight weeks to schedule, can also invite the patients to, in an office setting, take our patch and have it placed over the site of the lesion for 30 minutes over three settings. So if a cancer is diagnosed today, you schedule Mohs surgery, which is considered the gold standard six to eight weeks out because that is the wait time. The average wait time in the United States is about six to eight weeks. You could provide an option to have these three sittings one week apart of 30 minutes of our patch and come back for an examination on week four or five. If the lesion has been cured and the skin has become clear, then there is no need for surgical intervention. If, for some reason, our treatment fails, the patient can go on and get more surgery done and eventually become cancer-free." #MedicusPharma #PatchCure #BasalCellPatch #PatchTherapy #BCC #BasalCellCarcinoma #SkinCancer #Biotech #Dermatology #ClinicalTrials #Phase2Trial #SkinCancerTreatment medicuspharma.com Download the transcript here

Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma, has developed a novel, non-invasive treatment for basal cell carcinoma, the most common form of skin cancer. This cost-effective transdermal Skinject patch delivers a chemotherapeutic agent applied in a clinician's office over three sessions to remove the lesion, potentially avoiding the need for Mohs surgery, the current standard of care. Medicus is incorporating AI and advanced imaging techniques in its clinical trials to improve diagnosis and monitoring of the treatment's effectiveness.   Raza explains, "The gold standard to treat basal cell carcinoma of the skin is surgical intervention, generally speaking, all solid tumors to eliminate cancer if it is caught in the early stage. The treatment regimen is that you surgically take the malignant cells out. The same is true for basal cell carcinoma of the skin. It is a slow-growing cancer. It appears on areas of the body that are exposed to ultraviolet radiation, which is being exposed primarily to the sun. When the lesion appears and is diagnosed, the treatment available is what is called Mohs surgical procedure, which is a micrographic go around the lesion of the cancer and just curate out the cancer cells in a surgical suite done by an experienced surgeon."   "We are trying to disrupt by delivering a known chemotherapeutic agent through these uniquely designed, cellulose-based microneedle arrays, which can penetrate the dermis and deliver a chemotherapeutic agent at the site of the lesion and kill the cancer cells, thereby eliminating the need of surgical intervention." "It is currently in clinical trial, but post-approval, it is ready to commercialize. We hope that the dermatologists who are also trained to do Mohs surgery before scheduling the surgery, which usually takes about six to eight weeks to schedule, can also invite the patients to, in an office setting, take our patch and have it placed over the site of the lesion for 30 minutes over three settings. So if a cancer is diagnosed today, you schedule Mohs surgery, which is considered the gold standard six to eight weeks out because that is the wait time. The average wait time in the United States is about six to eight weeks. You could provide an option to have these three sittings one week apart of 30 minutes of our patch and come back for an examination on week four or five. If the lesion has been cured and the skin has become clear, then there is no need for surgical intervention. If, for some reason, our treatment fails, the patient can go on and get more surgery done and eventually become cancer-free." #MedicusPharma #PatchCure #BasalCellPatch #PatchTherapy #BCC #BasalCellCarcinoma #SkinCancer #Biotech #Dermatology #ClinicalTrials #Phase2Trial #SkinCancerTreatment medicuspharma.com Listen to the podcast here

Ny episode av Medicuspodden er ute. I denne episoden har vi delt ekslusivt innhold fra vår nye app, Fertilitetsresien. Mari Fevaag Heger, vår fertilitetscoacch snakker om det å møte julen når barneønske enda ikke er oppfylt. Hun deler av sine egne erfaringer, og gir noen konkrete tips og verktøy til hvordan du selv kan bidra til å gjøre julen litt bedre. Julen kan være som et forstørrelsesglass, på godt og vondt. Og vi i Medicus vet at mange har vanskelige følelser inn mot jul. Vi ønsker med denne episoden å dele noe av det medlemmene våre i Fertilitetsresien får, fordi vi tenker at det er viktig for enda flere.Vi ønsker deg en god lytting og en god jul! 

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce news that the company's Investigational New Animal Drug (INAD), featuring a dissolvable doxorubicin-containing microneedle array, has been granted Minor Use in Major Species Designation or MUMS by the U.S. Food and Drug Administration. This designation marks a significant step forward for Medicus Pharma's mission to revolutionize veterinary oncology. The FDA's MUMS designation is a pivotal milestone, akin to the Orphan Drug status for human medicines. It offers Medicus Pharma an extended 7-year period of exclusive marketing rights following approval or conditional approval, provided the company fulfills all regulatory requirements for maintaining the designation. This exclusivity positions the company to make a profound impact on treating external squamous cell carcinoma (SCC) in horses. The innovative doxorubicin-containing microneedle array is a patent-protected, dissolvable transdermal patch designed with cellulose-based microneedles. These microneedles are tip-loaded with doxorubicin, a potent chemotherapy agent. When applied, the microneedles penetrate the stratum corneum layer of the skin, creating temporary microchannels. This allows the microneedles to reach the tumor, dissolve, and release doxorubicin directly into the targeted area, effectively eradicating cancer cells while minimizing systemic side effects. Squamous cell carcinoma is a significant concern in horses, particularly in adult or aged animals with white or partially white coats. Breeds such as Appaloosa, Belgian, American Paint, and Pinto are especially susceptible. SCC typically develops in areas with minimal pigmentation and sparse hair, often around mucous membranes. Commonly affected areas include the eyes, lips, nose, anus, and external genitalia. With an overall incidence rate of 2-3%, this condition impacts a notable portion of the U.S. horse population, estimated to be between 6.6 and 7.25 million horses. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #CancerTreatment #HorseHealth #FDAApproval #InnovationInMedicine #SquamousCellCarcinoma #EquineCare #RazaBokhari #MUMSDesignation #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to to announce a new agreement with Swanielle to explore expanding the Phase 2 clinical study of a potential treatment for Basal Cell Carcinoma (BCC) into the Asia-Pacific region. The ongoing Phase 2 study, currently being conducted at nine clinical sites in the United States, has already enrolled over 25% of the targeted 60 patients. Medicus Pharma plans to conduct an interim analysis of the data in Q1 2025 and submit the findings to the FDA for a Type C meeting in Q2 2025. This meeting will focus on aligning the clinical development pathway and potentially advancing the study into a pivotal phase to accelerate development. Under the agreement, Swanielle, a healthcare consulting firm, will support Medicus in identifying pharmaceutical or biotech partners in Southeast Asia to facilitate the regional expansion of the study. This collaboration highlights Medicus Pharma's dedication to developing innovative solutions for BCC and strengthening its global clinical development strategy. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #BasalCellCarcinoma #CancerTreatment #ClinicalTrials #NonInvasiveTherapy #Phase2Study #SkinCancer #AsiaPacificExpansion #MedicalInnovation #FDAFastTrack #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

In this episode of Medicus, we're diving into the world of integrative medicine—a healthcare approach that goes beyond symptom management to treat the whole person. We talk with Dr. Jennifer Ron, an emergency medicine and integrative medicine physician about her practice. Join us as we explore how traditional medicine can work hand-in-hand with integrative practices to offer a more holistic path to health and wellness. Whether you're curious about what integrative medicine really means, looking for insights on how nutrition impacts health, or interested in how these practices can work within a traditional medical framework, this episode has something for everyone. Tune in and discover how integrative medicine might just be the key to creating a healthcare system that truly heals. To learn more about Dr. Ron's EPEP program, you can visit her website at: https://www.healingcancerfromwithin.com Episode produced by: Griffin K Johson Episode recording date: 10/07/2024 www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate

Fr. Wade Menezes talks about his new book, Stand Firm, Be Strong: A Men's Catholic Daily Devotional, scheduled for release on November 1st and Louis Brown, executive director of the Christ Medicus Foundation shares news about this Thursday's launch of a Policy Agenda for Religious Freedom in Health Care.

Fr. Wade Menezes talks about his new book, Stand Firm, Be Strong: A Men's Catholic Daily Devotional, scheduled for release on November 1st and Louis Brown, executive director of the Christ Medicus Foundation shares news about this Thursday's launch of a Policy Agenda for Religious Freedom in Health Care.

The autopsy has wide-ranging benefits on medicine, public health, and research. However, the rates of autopsies performed in the hospital have declined tremendously over the past several decades. The autopsy, accordingly, is often overlooked in medical education today. Emily Hagen, MD, has taken great interest in this.  In this episode, we speak with Emily (former Medicus producer!) about her firsthand experiences with the autopsy, dating back to her pre-med days and continuing throughout her time at Stritch School of Medicine. She is a fierce advocate for the autopsy's incorporation into medical education. While a medical student, Emily researched non-pathologist physicians' experiences with and views toward the autopsy and she launched an autopsy observation program for Loyola medical students. The associated research has been presented at multiple academic conferences. She also helped to curate Autopsy/Forensic Pathology modules for the PathElective, an internationally utilized resource.  As an aspiring internist, Emily discusses the relevance of the autopsy to physicians and the medical community at large.  Tune in now to learn more about this important and interesting topic!  To connect with Emily, email her at esh73@cornell.edu.  Episode produced by: Rasa Valiauga Episode recording date: 6/4/24 www.medicuspodcast.com | medicuspodcast@gmail.com  | Donate: http://bit.ly/MedicusDonate

In this episode, host Julien Stroumza sits down with Medicus member Jackie Tarsitano to discuss the alarming rise of genetic testing fraud, a multibillion-dollar scam that targets Medicare beneficiaries. Tune in as they explore the financial and ethical implications of this deceptive practice, shedding light on its impact on patients, healthcare providers, and the system as a whole.  Jackie can be reached at jtarsitano@luc.edu  Episode produced by: Jackie Tarsitano Episode recording date: 6/15/24 www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate

Ibn Sina verfasst das wohl einflussreichste Medizinbuch aller Zeiten. Wie ihm das gelang, obwohl er immer wieder auf der Flucht war, erzählt Andrea Sawatzi in dieser Folge.

Czy kiedykolwiek zastanawiałeś się, jak powieść historyczna może zmienić Twoje życie?Jeśli tak, to mam dla Ciebie coś specjalnego!W najnowszym odcinku mojego podcastu zabiorę Cię w fascynującą podróż przez karty „Medicusa” Noaha Gordona i pokażę, jak ta niezwykła książka może stać się Twoim osobistym narzędziem rozwoju.Dowiesz się m. in:Jak historia młodego lekarza z XI wieku może zainspirować Was do realizacji własnych marzeńDlaczego czytanie powieści historycznych to więcej niż rozrywka – to trening dla umysłu i duchaJak „Medicus” uczy nas odwagi, determinacji i otwartości na światW jaki sposób możesz wykorzystać lekcje z książki w swoim codziennym życiuPoznasz też moje osobiste doświadczenia z tą lekturą i dowiesz się, jak wpłynęła na moje postrzeganie świata i siebie samego.To nie jest zwykła recenzja książki.To praktyczny przewodnik po tym, jak literatura piękna może stać się Twoim sprzymierzeńcem w drodze do lepszego, bardziej świadomego życia.Gwarantuję, że po jego wysłuchaniu spojrzysz na czytanie z zupełnie nowej perspektywy.Pamiętaj!Subskrybuj „Porannik Kreatywny”, aby nie przegapić kolejnych historii i praktycznych porad.Jeśli chcesz być na bieżąco z nowymi odcinkami i inspirującymi historiami, koniecznie subskrybuj mój podcast i dołącz do wspólnoty Lepiej Teraz na Patronite!Zapraszam Cię do dołączenia do grona Patronek i Patronów z Patronite.pl, gdzie znajdziesz nigdzie niepublikowane odcinki podcastu oraz specjalny Newsletter.Będę bardzo wdzięczny, jeśli do nich dołączysz!

Et maintenant, on part à l'époque médiévale ! Adhérez à cette chaîne pour obtenir des avantages : https://www.youtube.com/channel/UCN4TCCaX-gqBNkrUqXdgGRA/join Pour soutenir la chaîne, au choix: 1. Cliquez sur le bouton « Adhérer » sous la vidéo. 2. Patreon: https://www.patreon.com/hndl Musique issue du site : epidemicsound.com Images provenant de https://www.storyblocks.com Abonnez-vous à la chaine: https://www.youtube.com/c/LHistoirenousledira Les vidéos sont utilisées à des fins éducatives selon l'article 107 du Copyright Act de 1976 sur le Fair-Use. Sources et pour aller plus loin: Philippe Brenot et Laetitia Coryn, Sexe Story. La première histoire de la sexualité en BD, Montréal, Guy Saint-Jean, 2016 Reay Tannahill, Le sexe dans l'histoire, Paris, Marabout, 1982. Maryse Jaspard, Sociologie des comportements sexuels, Paris, Découverte, 2005. Sylvie Steinberg (dir.), Une histoire des sexualités, Paris, PUF, 2018 Robert Muchembled, L'orgasme et l'Occident, Paris, Seuil, 2015. Lo Duca, Histoire de l'érotisme, Paris, Pygmalion, 1979. Yvonne Knibiehler, La sexualité et l'histoire, Paris, Odile Jacob, 2002. Ollie Wells, « Amour, Sexe et Mariage en Grèce Antique », World History Encyclopedia, 25 mars 2021. https://www.worldhistory.org/trans/fr/2-1713/amour-sexe-et-mariage-en-grece-antique/#:~:text=Les%20Grecs%20anciens%20ne%20considéraient,relation%20avec%20un%20autre%20homme. Michel Foucault, Histoire de la sexualité, t. I La Volonté de savoir, Paris, Gallimard Gérard Lomenec'h, L'érotisme au Moyen Âge, Rennes, Éditions Ouest-France, 2018. Jean-Claude Bologne, La Naissance interdite, stérilité, avortement, contraception au Moyen âge, Paris, O. Orban, 1988. Katherine Harvey, The Fires of Lust. Sex in the Middle Ages, London, Reaktion Books, 2021, Didier Lett, « L'Occident médieval », dans Une histoire des sexualités, sous la dir. de Sylvie Steinberg, Paris, PUF, 2018, p.95-167. Didier Lett, Hommes et femmes du Moyen Âge. Histoire du genre XIIe-XVe siècle. Paris, Armand Colin, 2023. Jean-Louis Flandrin, Un temps pour embrasser. Aux origines de la morale sexuelle occidentale (VIe-XIe siècle), Paris, Seuil, 1983. Jacques Rossiaud, Amours vénales : la prostitution en Occident, XIIe-XVIe siècle, Paris, Aubier-Flammarion, 2010. Jacques Rossiaud, Sexualités au Moyen Âge, Gisserot, 2002. Jacques Rossiaud, « Comment on faisait l'amour au Moyen Âge », L'Histoire, août 1999. https://www.lhistoire.fr/comment-on-faisait-lamour-au-moyen-age Arnaud De la Croix, L'érotisme au Moyen Âge, le corps, le désir, l'amour, Paris, Tallendier, 1999. Jean Verdon, S'amuser au Moyen Âge, Paris, Tallendier, 2003 (1980). Jean Verdon, La vie quotidienne au Moyen Âge, Paris, Perrin, 2015. Jean Verdon, Le plaisir au Moyen Âge, Paris, Perri, 1996. Jean Verdon, L'amour au Moyen Âge. La chair, le sexe et le sentiment, Paris, Perrin, 2006. Bernard Ribémont, Sexe et amour au Moyen Âge, Genève, Klincksieck, 2007. Cyrille Vogel, Le pécheur et la pénitence au Moyen Âge, Paris, Cerf, 1982. Ferrucio Bertini, Les femmes au Moyen Âge, Paris, Hachette, 1991. Danielle Jacquart et Claude Thomasset, Sexualité et savoir médical au Moyen Âge, Paris, PUF, 1985. Mark Jordan, L'invention de la sodomie dans la théologie médiévale, Paris, Epel, 2007 (1997). Ruth Mazo Karras, Sexuality in medieval Europe. Doing unto others, New York and London, Routledge, 2005. Leah Otis, Prostitution in Medieval Society: the History of an Urban Institution in Languedoc, Chicago, 1985. Christian-Georges Schwentzel, Débauches antiques. Comment la Bible et les Anciens ont inventé le vice, Paris, Vendémiaire, 2023. Thomas Tentler, Sin and Confession on the Eve of the Reformation, Princeton, 1977. Eleanor Janega, The Once and Future Sex, going Medieval on Women's Roles in Society, New York, W.W. Norton & Company inc., 2023. Jack Hartnell, Medieval Bodies. Life, Death and Art in the Middles Ages, London, Wellcome Collection, 2018. R. Nelli, L'érotique des troubadours, Toulouse, Privat, 1984 (1963). Jean-Pierre Poly, Le chemin des amours barbares. Genèse médiévale de la sexualité européenne, Paris, Perrin, 2003. Priscille Lamure, « Le pénitentiel de Worms, pour une approche décomplexée de la sexualité au Moyen Âge », Savoir d'histoire, 27 juin 2015. https://savoirsdhistoire.wordpress.com/2015/06/27/le-penitentiel-de-worms-pour-une-approche-decomplexee-de-la-sexualite-au-moyen-age/ François Gagnon, « Le Corrector sive Medicus de Burchard de Worms (1000-1025) : présentation, traduction et commentaire ethno-historique », Mémoire de l'Université de Montréal, 2010. Autres références disponibles sur demande. #histoire #documentaire #sexualité #moyenage #sexuality middleage

In this 4th year medical student (MS4) series, we discuss the field of Psychiatry. Our guest, Julia Versel, shares advice on how to set yourself up for success regarding matching into this increasingly competitive specialty and shares tips to help you stand out both on paper and in person. Julia Versel, MD, MSc is a current resident at Brigham and Women's Hospital/Harvard Medical School Psychiatry Residency Program. She is passionate about medical education, with a particular interest in incorporating medical student mentorship into her career. Please reach out to the Medicus team if you would like to get in touch with her! To learn more about the field, check out these resources: Psychiatry Student Interest Group Network (PsychSIGN): https://www.psychsign.org/ AADPRT Psychiatry Training Resources: https://www.aadprt.org/trainees/psychiatry-training APA Roadmap to Applying for Psychiatry Residency: https://www.psychiatry.org/getmedia/b7007db1-b815-45fa-93bd-1f1eaf3dff99/APA-Roadmap-to-Psychiatric-Residency.pdf APA Resources for Medical Students: https://www.psychiatry.org/residents-medical-students/medical-students Episode produced by: Rasa Valiauga Episode recording date: 4/25/24 www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate

Pastor Mattie teaches on the Christus Medicus model of the atonement, painting a picture of the Cross as not only a means to our deliverance and forgiveness, but also our healing. Support the Show.

Eine bessere Gesundheitsversorgung für alle Bürger*innen – dies ist das Ziel der neuen Gesundheitsplattform „Medicus“, die 2024 in Baden-Württemberg aufgebaut werden soll. Auf einer zentralen Online-Plattform sollen Kliniken in Zukunft Gesundheitsdaten austauschen können.

Het is vandaag tien jaar geleden dat voormalig minister van Volksgezondheid en D66-prominent Els Borst is vermoord. Wat waren de hoogtepunten, maar ook de dieptepunten van de carriere van Els Borst? Hoe werd zij als niet-feminist een vrouwelijk rolmodel? En wat is haar nalatenschap? We bespreken het met Historicus Nele Beyens. Zij schreef twee jaar geleden 'Els Borst, Medicus in de politiek'. Presentatie: Jan van Poppel

A clinical stage, multi-strategyholding company focused on investing in and accelerating novel life sciencesand bio-technology companies through FDA approved clinical trials. Through theirdiverse experience and extensive industry network, They are building Medicusinto a leading pharmaceutical holding company, committed to delivering bettertreatment outcomes and alleviate pain and suffering.Utilizing a thesis driven collaborative process, they identify,acquire and advance relatively de-risked clinical stage assets through clinicaldevelopment and commercialization.

Looking for a good read, show, and/or podcast (besides Medicus of course)? It is in fact the holidays, so what are you waiting for? Tune in now to our third Medicus Reading List episode! You will hear Medicus team members recommend great books and other media content from the medical world.  Content covered:  -Good Reasons for Bad Feelings by Randolph M. Nesse -The House of God By Samuel Shem -Dopesick (show) -Spoonful of Sugar Podcast and White Coat Investor Podcast -Knock Knock Eye Podcast and Knock Knock, Hi! Podcast Episode produced by: Emily Hagen Contributors: John Engelbert, Isabelle Tan, Emily Hagen, Rasa Valiauga, Deborah Chen www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate --- Send in a voice message: https://podcasters.spotify.com/pod/show/medicus/message

Medicus, primera plataforma digital para telemedicina formada por médicos latinos,anunció que inició a ofrecer sus servicios corporativos para empresas en Latinoamérica,incluyendo República Dominicana, donde los pacientes pueden consultarse de formavirtual con doctores acreditados e hispanohablantes en los Estados Unidos. Para vercon más detalles todo lo que trae esta plataforma, conversamos ahora con el doctorJosé Medina-Bairan, quien es egresado de dela Faculta de Medicina de la UniversidadNacional Pedro Henríquez Ureña, además realizó estudios en medicina interna en laciudad de Nueva York.

Andrew, Matt, and Claude discuss Australia's property market and how to fix it, plus Pro Medicus winning its largest contract to date, as well as Supply Network and Siteminder. Follow us on Twitter: @BabyGiantsPodSubscribe to our channel: https://www.youtube.com/channel/UCSXgHHJ4XjWK-r1k4O0pj1g-----0:36 - Good News2:35 - Property13:16 - Pro Medicus (ASX: PME) wins its largest contract to date15:20 - Supply Network (ASX: SNL)30:19 - Siteminder (ASX: SDR)38:51 - Market Chat/Property Pt. 2

Pro Medicus Limited, 2023 Earnings Call, Aug 15, 2023

Pro Medicus Limited, H1 2023 Earnings Call, Feb 15, 2023

Today's guests are the dynamic duo Nadine Keegan and Tom Medicus. I was able to catch them both at the same time while Nadine is visiting Tom's studio in Austria. Although their work is strikingly different, they both have done a brilliant job bringing meaningful topics and statements into their work. Keep listening and you'll agree! Join me as I crack it wide open... Nadine: After spending 3 years studying fine art photography at RMIT and PIC, she became disillusioned with the orthodox methods of image making and work style of a fine art photographer.  A few years past and many less artistic pursuits were explored when, with a visit to the solar-punk stained glass mural Cosmovitrial in Toluca, Mexico she finally discovered the creative industry which aligned with her ideals. While realizing the potential that exists within the craft that I had not yet seen in Australia.  Solidifying her obsession with research into the stained glass window's development through the 20th century, with the manifestations of the Arts and Crafts anti-industrialisation ideals embedded in it's design and construction.  Through her work, she celebrates both the legacy of the craft laid out before her and the potentiality of the materials when manipulated with a contemporary perspective and up-to-date technology. Her experience includes custom stained glass fabrication, heritage restoration, architectural glass work and exhibition works. To see more of Nadine's work, her instagram is @nadinekeegan. Tom: Thomas Medicus is a visual artist based in Innsbruck, Austria. Best known for his anamorphic cubes he also works in other fields such as illustration, animation, digital art, stained glass, restoration and conservation as well as public art. He studied social work at MCI Innsbruck before attending the Glasfachschule Kramsach, a school for glass art, where he earned a master glaziers degree later. In addition to his independent activity as a freelance artist, he was employed in the long-standing firm for stained glass windows Tiroler Glasmalerei for seven years. From the beginning of 2021 he became completely independent and founded his company Studio Medicus. To see more of Tom's work, his instagram is @tomedicus. Nadine's:sainer.org regantamanui.com@jaaaaameswilson@jordanb_art davidwrightstudio.com@duckragu @george.goodnow Hannah Gregory runaglassworks.comJenna Zavattiero@stayglassyglassTom's:ROA@roa_archivePat Perry@heypatyeahJudith Schaechterrunaglassworks.comOlafur Eliassonolafureliasson.netThis episode's sponsors:Canfield Technologies Canfield sets the standard for the Stained Glass industry. Paul Wissmach Glass Co. Your Source of Colored Sheet GlassSupport the show

Hey, you! Yeah, YOU! What are you doing reading this podcast description when you could be reading one of the books recommended by Medicus team members in our newest reading list episode?!?! Stop wasting time and get going! Content covered: Just Mercy: A Story of Justice and Redemption by Bryan Stevenson God's Hospital: A Doctor, a Hospital, and a Pilgrimage to the Heart of Medicine by Victoria Sweet “What I Would Give” by Rafael Campo (poem) When Breath Becomes Air by Paul Kalanithi I Shall Not Hate: A Gaza Doctor's Journey on the Road to Peace and Human Dignity by Izzeldin Abuelaish Being Mortal by Atul Gawande Many Lives, Many Masters by Brian Weiss Episode produced by: Brendan Connolly Contributors: Monica Contractor, Rasa Valiauga, Lauren Hekman, Isabelle Tan www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate --- Send in a voice message: https://anchor.fm/medicus/message

Content Warnings: Body horror, violence, unethical medical experimentation, coercion, possible misophonia triggers. --- In which the whole and terrible truth is laid bare. -- Frederick Kent is played by Jeremy B Detective Eugene Clifford is played by Scott Paladin Dr. Albert von Leichenberg is played by Vic C Gloria Franklin is played by Rebecca C Lorraine Stanley is played by Jenna R Agent Barker is played by Stephen B/Nessrocker The Radio Announcer is played by Kale Brown --- A Most Vital Art is written by Lee Seguinte, and edited by Erik Seguinte, as a product of Law of Names Media, based on the work of S. J. Ryker. --- The Blake Skye A Most Vital Art website: https://www.blakeskyepi.com/a-most-vital-art The Law of Names Media website: https://lawofnames.com/ Join the Blake Skye: Private Eye Discord https://discord.gg/ESNjBPQay8 Join the Law of Names Discord discord.lawofnames.com

The original creators of the Medicus Podcast are wrapping up their first year of residency and offer their perspectives on being an intern. Alek Druck - Urology, University of South Florida Mara Peterson - Internal Medicine, Oregon Health and Science University Nathan Burstedt - Preliminary Medicine Year, Loyola University Medical Center (going into Internal Medicine at Overland Park Regional Medical Center) Joshua Lewis - Preliminary Medicine Year, Advocate Lutheran General Hospital (going into Physical Medicine and Rehabilitation at Montefiore Medical Center) Episode produced by: Rasa Valiauga, Katie Mott Episode recording date: January - June, 2022 www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate --- Send in a voice message: https://anchor.fm/medicus/message